头孢哌酮舒巴坦钠治疗医院获得性肺炎的疗效观察

A Survey of Cefoperazone Sulbactam Sodium Treatment of Hospital-acquired Pneumonia

目的:探讨头孢哌酮舒巴坦钠治疗社区获得性肺炎的临床疗效和不良反应,为社区获得性肺炎的治疗提供依据。方法:将我院收治并诊断为社区获得性肺炎的病例76例随机分为研究组和对照组,每组38例,两组均给予社区获得性肺炎的常规治疗,对照组患者应用左氧氟沙星200mg/次,静脉滴注,每日2次,疗程5-7d。研究组患者应用头孢哌酮舒巴坦钠2g/次,静脉滴注,每日两次,疗程5-7d。观察两组患者临床疗效和治疗期间不良反应发生情况。结果:研究组体温恢复正常时间为(16.5±1.3)h,总有效率为97.4%(37/38);对照组体温恢复正常时间为(28.5±1.5)h,总有效率为81.6%(31/38),两组数据间比较有统计学差异(P<0.05);研究组不良反应发生率为7.9%,对照组不良反应发生率为10.5%,两组患者不良反应发生率无统计学差异(P>0.05)。结论:头孢哌酮舒巴坦钠治疗社区获得性肺炎的临床疗效较好,不良反应较低,值得临床推广应用。

Objective： To investigate the clinical efficacy and adverse reactions of cefoperazone sulbactam sodium in the treatment of community-acquired pneumonia.Method： 76 cases of community-acquired pneumonia were randomly divided into study group and control group,38 cases in each group,both groups were given community-acquired pneumonia conventional treatment,the control group were given levofloxacin 200mg,intravenous infusion,5 to 7 days for a course.The study group were given cefoperazone sulbactam 2g,intravenous infusion,twice daily,5 to 7 days.Result： The body temperature in the study group returned to normal time（16.5 ± 1.3） h,the total effective rate was 97.4%（37/38）;control group,body temperature returned to normal time（28.5 ± 1.5） h,the total effective rate was 81.6%（31 / 38）,（P 0.05）;study group of adverse reactions was 7.9%,the incidence of adverse in the control group was 10.5%,（P 0.05）.Conclusion： The clinical efficacy of cefoperazone sulbactam sodium treatment of community-acquired pneumonia is better,adverse reactions is less,worthy of clinical application.